CSChangcheng Shi

Changcheng Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Changcheng Shi has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Lihong Liu

    Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Capital Medical University

    3 shared publications
  • Nengming Lin

    Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China

    3 shared publications
  • Xinyi Li

    China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China

    3 shared publications
  • Junbo Xia

    Department of Respiratory Medicine Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine Hangzhou China

    2 shared publications
  • Limin Wang

    Department of Pulmonary and Critical Care Medicine, Affiliated Hangzhou First People Hospital, School of Medicine, Westlake University, Hangzhou, China

    2 shared publications
  • Liusheng Wang

    Department of Respiratory Medicine Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine Hangzhou China

    2 shared publications

Latest Publications

  • Open Access

    Pharmacist-Led Integrated Management for Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

    by Xinyi Li, Xuedi Ma, Wangjun Qin, Changcheng Shi, Lihong Liu, Chen Wang

    Purpose: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, and suboptimal medication management contributes to exacerbations and preventable healthcare utilization. Pharmacist-led integrated care has the potential to improve medication use and clinical outcomes. We conducted a systematic review and meta-analysis to evaluate the effects of pharmacist-led interventions in COPD. Methods: This systematic review and meta-analysis was conducted and reported in accordance with PRISMA 2020. We searched PubMed, Embase, and Web of Science from inception until June 23, 2025. Randomized controlled trials (RCTs) assessing the effects of pharmaceutical care on clinical outcomes in COPD patients were included. A random-effects model was used to estimate pooled relative risks (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane Risk of Bias tool. Results: A total of 11 randomized controlled trials involving 2313 participants were included. Pharmacist-led interventions were associated with a lower risk of exacerbation-related hospital admissions (RR = 0.43, 95% CI: 0.33– 0.55). Improvements in medication adherence and higher smoking cessation rates were also observed. Improvements in health-related quality of life were reported; however, substantial heterogeneity was present. In contrast, effects on COPD Assessment Test scores and objective disease measures, including lung function, were non-significant. Overall study quality was variable, with many trials being small and at high risk of bias. Conclusion: Pharmacist-led interventions in COPD may improve selected medication-related and patient-centered outcomes; however, the available evidence is heterogeneous and limited by study quality and inconsistent effects across outcomes. These findings should be interpreted cautiously, and well-designed, adequately powered trials with standardized outcomes are needed before robust conclusions regarding clinical effectiveness can be drawn.


  • Open Access

    Current Status and Research Trends in Deprescribing: A Bibliometric Review

    by Changcheng Shi, Xinyi Li, Yan Wu, Wangjun Qin, Lihong Liu

    Background: Polypharmacy has emerged as a major global public health concern. To mitigate its adverse effects, deprescribing has been introduced and integrated into clinical practice. This study aims to analyze the current research landscape and identify emerging trends in deprescribing from a bibliometric perspective. Methods: Relevant studies on deprescribing published prior to December 2024 were retrieved from the Web of Science Core Collection database. Bibliometric analysis and visualization of co-authorship, citation, co-citation, co-occurrence, and burst detection were performed using VOSviewer, CiteSpace, and Bibliometrix. Results: A total of 1809 publications were identified, with a marked increase over the past decade. The field is dominated by contributions from developed countries, notably the United States, Australia, and Canada. Studies primarily focus on chronic conditions, such as psychiatric disorders, cardiometabolic diseases, and chronic pain, and the medications used to treat them. Influential publications highlighted barriers and facilitators of deprescribing, deprescribing tools, and deprescribing interventions and their associated outcomes. Burst detection analysis pointed to increasing attention on pharmaceutical care and implementation science. Conclusion: This study presents the first comprehensive bibliometric overview of deprescribing. The findings demonstrate that the field has grown rapidly but remains dominated by developed countries and a limited set of chronic diseases. The integration of implementation science frameworks emerges as a promising approach to enhance the design and evaluation of deprescribing interventions. Future studies should broaden their scope to include a wider range of diseases and medications, and encourage greater participation from developing countries.


  • Open Access

    Assessing Medication Literacy and Its Determinants in Chinese Patients with Multimorbidity

    by Xinyi Li, Changcheng Shi, Lihong Liu, Yibo Wu

    Purpose: To investigate the medication literacy and influencing factors among patients with multimorbidity. Methods: A cross-sectional survey was conducted to assess medication literacy using the medication literacy scale in patients with multimorbidity. Data were collected between June 20 and August 31, 2023, using stratified and quota sampling methods. The Wilcoxon tests or Kruskal–Wallis tests, Pearson’s correlation analysis, and multiple stepwise linear regression were employed for the analysis. Results: 3,955 patients with multimorbidity were included, with the average medication literacy score of 18.56± 4.52 (scale range: 6– 30). Younger age groups (18– 30, 31– 44, 45– 59 years) had higher medication literacy than those aged 60 years or older (β = 0.11, 0.14, 0.17 respectively; all P < 0.01). Higher education levels (middle/secondary degree, college/university degree, postgraduate degree) correlated with higher medication literacy compared to primary or lower education (β =0.21, 0.28, 0.13 respectively; all P < 0.01). Currently married (β =0.09, P < 0.01), unmarried (β =0.15, P < 0.01), and divorced individuals (β =0.06, P < 0.01) all exhibited higher medication literacy compared to widowed individuals. Compared with people living in Eastern China, those in Central/Western China (β =– 0.06, – 0.07, respectively; all P < 0.01) had lower medication literacy. People whose area was urban (β =0.07, P < 0.01) showed higher medication literacy compared with the rural. A higher score of depressive symptoms (β =– 0.20, P < 0.01) was negatively correlated with medication literacy, and a higher level of social support (β = 0.17, P < 0.01) was positively correlated with medication literacy. Conclusion: It is critically important to improve medication literacy in patients with multimorbidity, particularly by optimizing medication instructions for understanding. Tailored interventions targeting older, less educated, rural, and central/western populations with emphasis on depression management and social support are needed. Study Registration: ChiCTR2300072573.


  • Guidance Documents for Off‐Label Drug Use Management for Chinese Health Care Institutions: A Scoping Review

    by Changcheng Shi, Yingying Yang, Changling Wu, Limin Wang, Yehua Dong, Yajun Qi, Lingling Hu, Ling Chen, Qingyu Li, Qianqian Jiang, et al.

    Background: Off‐label drug use (OLDU) is a common practice in health care institutions, and numerous guidance documents have been developed to guide the management of OLDU in China. This scoping review aims to compare these documents and identify existing issues.Methods: PubMed, EMbase, three Chinese databases, the National Public Service Platform for Standards Information and the official websites of pharmaceutical‐related associations were searched to identify guidance documents relevant to the management of OLDU for Chinese health care institutions. We extracted and compared the recommended practices for various aspects of OLDU management, including management systems, organizational structure, prerequisites for OLDU, approval processes, evidence‐based evaluation, informed consent, and other related aspects.Results: A total of 16 guidance documents were included, comprising 12 expert consensuses, 2 practice guidelines, and 2 group standards. Only six documents provide specific requirements for the establishment of management systems. Management of OLDU requires involvement from multiple departments or committees, yet only a few documents explicitly delineate the supervisory authority, and the responsibilities of the parties involved. These documents also show significant disparities in their approval process, evidence‐based evaluation, and informed consent recommendations. Furthermore, only a minority of the documents provide specific requirements for training and assessments focused on OLDU and improving adverse reaction monitoring.Conclusion: These guidance documents differ significantly in their specific recommendations for the management of OLDU and lack sufficient emphasis on certain critical aspects. It may be beneficial for health administrative authorities to promote the development of unified national guidelines.


  • Top Cited Papers
    Open Access

    Detoxification and underlying mechanisms towards toxic alkaloids by Traditional Chinese Medicine processing: A comprehensive review

    by Qiyuan Shan, Wei Yu, Qiongfang Xu, Ruina Liu, Shuye Ying, Jie Dong, Yini Bao, Qiang Lyu, Changcheng Shi, Junjie Xia, et al.


  • Open Access

    Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: A systematic review and meta‐analysis

    by Changcheng Shi, Qiyuan Shan, Junbo Xia, Liusheng Wang, Linling Wang, Lei Qiu, Yaping Xie, Nengming Lin, Limin Wang

    Background: An increasing number of cases of invasive pulmonary aspergillosis (IPA) complicating influenza have been described. We performed a meta‐analysis to estimate the incidence, risk factors and outcomes of IPA in patients with influenza.Methods: A systematic search was conducted in the PubMed, EMBASE and Cochrane Library databases from their inception to 31 August 2021 for eligible studies. Data on the incidence and risk factors of and mortality due to IPA in influenza patients were pooled using a random‐effects model. Sensitivity analyses restricted to severe influenza requiring intensive care unit (ICU) support and multiple subgroup analyses were performed.Results: Fourteen studies involving 6024 hospitalised patients with influenza were included. IPA was estimated to occur in 10% of influenza patients, with a mortality rate of 52%. Similar incidence (11%) and mortality (54%) estimates for IPA were observed in the sensitivity analysis including severe cases requiring ICU support. Subgroup analysis by geographical location showed a similar IPA rate between European (10%) and non‐European (11%) studies. The IPA rate in the subset of nine studies using the modified AspICU criteria was 13%. Most subgroup analyses showed ≥50% mortality in IPA patients. Several predictors for IPA susceptibility were identified, including male sex, smoking history, chronic lung disease, influenza A (H1N1), severe conditions requiring supportive therapy, corticosteroid use before admission, solid organ transplant and haematological malignancy.Conclusions: The IPA is common in individuals with severe influenza, and the prognosis is particularly poor. Influenza patients, especially those with high‐risk factors, should be thoroughly screened for IPA.


  • Open Access

    Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta‐analysis

    by Changcheng Shi, Junbo Xia, Jian Ye, Yaping Xie, Weizhong Jin, Wei Zhang, Liusheng Wang, Xuping Ding, Nengming Lin, Limin Wang

    Aims: The association of renal function and linezolid‐induced thrombocytopaenia (LIT) remains controversial. We performed a meta‐analysis to determine whether impaired renal function is associated with an increased LIT risk.Methods: We conducted a systematic search of PubMed, EMBASE and the Cochrane Library from inception to February 2021 for eligible studies evaluating the relationship between renal function and LIT. Indicators of renal function included renal impairment (RI), severe RI, haemodialysis status, creatinine clearance rate (Ccr) and estimated glomerular filtration rate (eGFR). Unadjusted and adjusted estimates and 95% confidence intervals (CIs) were calculated separately using a random‐effect model.Results: A total of 24 studies with 3580 patients were included in the meta‐analysis. RI patients had an increased LIT risk compared to non‐RI patients in both the unadjusted (OR 3.54; 95% CI 2.27, 5.54; I2 = 77.7%) and adjusted analyses (OR 2.51; 95% CI 1.82, 3.45; I2 = 17.9%). This association persisted in the subset of studies involving only patients receiving a fixed conventional dose (600 mg every 12 h) and other subgroup analyses by ethnicity, sample size and study quality. Moreover, the LIT risk was significantly higher in patients with severe RI and haemodialysis than in patients without severe RI and haemodialysis. The eGFR and Ccr were significantly lower in LIT patients than in non‐LIT patients.Conclusions: Impaired renal function is associated with an increased risk of LIT. A reduced linezolid dose may be considered in RI patients at a low risk of treatment failure, ideally guided by therapeutic drug monitoring.